Document Detail

Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study.
MedLine Citation:
PMID:  19963164     Owner:  NLM     Status:  MEDLINE    
We undertook a retrospective cohort study comparing infection in solid organ transplant recipients receiving alemtuzumab (n = 726) versus basiliximab (n = 215) or antithymocyte globulin (ATG) (n = 85). Eighty-one percent of patients had kidney transplants. Overall, 33% of patients in the alemtuzumab group (240/724) developed infection compared with 40% (87/215) in the basiliximab group (odds ratio [OR], 0.72; 95% confidence interval [CI], 0.53-0.99; P = .04). The frequency of infection was similar in the alemtuzumab and ATG groups (33% versus 36%, respectively, P = .53). The frequency of fungal infections, most caused by Candida spp., was similar in the alemtuzumab and basiliximab groups (10% versus 9%); disseminated fungal infection occurred in 68% of the patients with fungal infection receiving alemtuzumab and in 30% of the patients with fungal infection receiving basiliximab (OR, 4.76; 95% CI, 1.58-14.28; P = .003). Basiliximab posed a higher risk than alemtuzumab for infection. Disseminated candidal infections were more common in patients receiving alemtuzumab.
Nasia Safdar; Jeannina Smith; Valerie Knasinski; Colleen Sherkow; Casey Herrforth; Stuart Knechtle; David Andes
Related Documents :
11816244 - Therapeutic dilemma of fluconazole prophylaxis in intensive care.
6754414 - Asbestos exposure and aspergillus infection.
2512744 - An autopsy case of disseminated trichosporonosis with candidiasis of the urinary bladder.
883094 - Anaphylactoid purpura in a horse.
8306714 - Size dependent variation in the fractal dimensions of herpes simplex epithelial keratitis.
17470274 - Role of previous hospitalization in clinically-significant mrsa infection among hiv-inf...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Diagnostic microbiology and infectious disease     Volume:  66     ISSN:  1879-0070     ISO Abbreviation:  Diagn. Microbiol. Infect. Dis.     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-12-07     Completed Date:  2010-03-01     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8305899     Medline TA:  Diagn Microbiol Infect Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  7-15     Citation Subset:  IM    
Department of Medicine, Section Infectious Diseases, University of Wisconsin, Madison, WI 54792, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / administration & dosage,  adverse effects*
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / administration & dosage,  adverse effects*
Antilymphocyte Serum / adverse effects,  therapeutic use
Cohort Studies
Graft Rejection / drug therapy
Immunocompromised Host / drug effects
Immunoglobulin G / administration & dosage,  adverse effects
Immunosuppressive Agents / adverse effects*,  therapeutic use
Kidney Transplantation / adverse effects*
Middle Aged
Mycoses / etiology,  microbiology
Opportunistic Infections / etiology*,  microbiology,  virology
Recombinant Fusion Proteins / administration & dosage,  adverse effects
Retrospective Studies
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Neoplasm; 0/Antilymphocyte Serum; 0/Immunoglobulin G; 0/Immunosuppressive Agents; 0/Recombinant Fusion Proteins; 0/basiliximab; 3A189DH42V/alemtuzumab; CUJ2MVI71Y/daclizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Adequate iodine intake of Slovenian adolescents is primarily attributed to excessive salt intake.
Next Document:  The natural history and pathophysiology of flexible flatfoot.